IMRX vs SLB · $124.2M cap vs P/E 12, rev $35.71B
Immuneering Corp (IMRX) versus Schlumberger NV (SLB) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Schlumberger NV (SLB) is a oil & gas equipment & services company listed on US.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported SLB revenue for 2025-12-31 was $35.71B. Net income was $3.37B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
IMRX currently screens at market cap $124.2M. SLB currently screens at market cap $48.16B and trailing P/E 12.1.
Not investment advice. Open the IMRX and SLB stock pages for the full models.
Not investment advice.